Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 71 134 sessions, April 23, 2026 to November 2, 2026
- Largest daily move
- +83.3% close of July 22, 2026
- 1-month change
- -80.3% closing prices, October 2, 2026 to November 2, 2026
Company Description
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing antimicrobial drug candidates for infectious diseases. The company’s research is centered on the Bisphosphocin® class, a novel class of fast-acting, broad-spectrum antimicrobials discovered by Lakewood-Amedex and intended to address bacterial infections, including strains associated with antimicrobial resistance such as MRSA and VRE. Its common stock trades on the Nasdaq Capital Market under the symbol LABT following an April 2026 direct listing.
Antimicrobial platform and lead compound
The company’s lead compound, Nu-3, is being developed as a topically delivered antimicrobial treatment for infected diabetic foot ulcers. Lakewood-Amedex describes Nu-3 as part of its Bisphosphocin platform. Reported in vitro data for the class indicate rapid bacterial killing through pH- and concentration-dependent destabilization of bacterial cell membranes. The platform is also being explored in preclinical studies for potential use in complicated urinary tract infection and pulmonary infections.
Lakewood-Amedex’s operating model is based on advancing proprietary antimicrobial compounds through research, preclinical work, clinical development, and regulatory preparation. As a clinical-stage biotechnology issuer, the company’s durable business profile is defined by its drug-development pipeline rather than commercial product sales.
Public company status
Lakewood-Amedex Biotherapeutics is incorporated in Nevada and maintains principal executive offices in University Park, Florida. Its SEC registration materials identify the company within pharmaceutical preparations. Public-company disclosures for LABT cover securities registration, corporate governance, board composition, capital structure, business risks, and updates related to its antimicrobial development programs.
Stock Performance
Lakewood-Amedex Biotherapeutics (LABT) closed at $0.1833 on November 2, 2026. Over the past month, the price has lost 80.3%.
LABT Metrics & Rankings
Price returns through November 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Lakewood-Amedex Biotherapeutics has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial. View all LABT news →
SEC Filings
Lakewood-Amedex Biotherapeutics has filed 10 recent SEC filings, including 2 Form 8-K, 2 Form SCHEDULE 13G, 1 Form EFFECT, 1 Form S-1. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LABT SEC filings →
Financial Highlights
Lakewood-Amedex Biotherapeutics reported diluted earnings per share of -$8.40 in FY2025. The company generated -$1.9M in operating cash flow. The current ratio was 0.13, measuring current assets divided by current liabilities.
Upcoming Events
Topline data release
Nu-3 Topline Data
Phase 2a topline data
Topline data release
Lakewood-Amedex Biotherapeutics has 4 upcoming scheduled events. The next event, "Topline data release", is expected in Q1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the LABT stock price.
Short Interest History
Short interest in Lakewood-Amedex Biotherapeutics (LABT) currently stands at 90.0 thousand shares, down 31.1% from the previous reporting period, representing 6.3% of the float. Since the latest stock split, short interest has increased by 274.7%, measured from July 2026.
Days to Cover History
Days to cover for Lakewood-Amedex Biotherapeutics (LABT) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.
LABT Company Profile & Sector Positioning
Lakewood-Amedex Biotherapeutics (LABT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing LABT often look at related companies in the same sector, including SciSparc Ltd. (SPRC), CDT Equity Inc. (CDT), Lunai Bioworks Inc (LNAI), Valion Bio, Inc. (VBIO), and Biodexa Pharmaceuticals plc (BDRX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LABT's relative position within its industry.